血栓性疾病严重威胁着人类健康，在尽可能短的时间内确诊血栓并快速恢复缺血组织再灌注是诊治血栓性疾病的关键。结合前期研究基础及材料的特性，本项目拟构建诊疗一体化的的血栓分子探针。高分子材料PLGA为载体，第三代溶栓药物替奈普酶作为探针靶向组件及溶栓药物，当其进入血管后能特异性靶向血栓纤维蛋白实现递送探针及药物溶栓的功能；多模态成像材料Bi2S3和全氟己烷（PFH）作为内核，能实现CT及光声成像精准诊断血栓，同时，联合低强度聚焦超声（LIFU）致相变技术触发PFH发生液-气相变，实现血栓“内轰炸”，达到促进探针内渗和相变溶栓的目的。通过体内外实验验证其靶向性及多模态显影效果，研究药物-相变溶栓这种新型高效溶栓方式的溶栓效果及其溶栓机制，多模态成像实时评估溶栓进程及效果，以期研发一种高效、方便、经济、无创的兼具诊断和治疗的“多合一”血栓分子探针，实现血栓的快速精准诊疗。

Thrombotic diseases are a serious threat to human health. As soon as possible to diagnose thrombosis, rapid recovery of ischemic tissue reperfusion is the key to the diagnosis and treatment of thrombotic diseases. Combining the basis of previous research and the characteristics of materials, this project plans to construct a thrombotic molecular probe integrated with diagnosis and treatment. The polymer material PLGA is used as a carrier, and the third-generation thrombolytic drug tenepase is used as a probe targeting component and a thrombolytic drug. When it enters a blood vessel, it can specifically target thrombus fibrin to realize delivery probe and drug thrombolysis. Multi-modal imaging materials Bi2S3 and perfluorohexane (PFH) are used as cores to accurately diagnose thrombus by CT and photoacoustic imaging. At the same time, combining with low-intensity focused ultrasound (LIFU)-induced phase transition technology triggers liquid-gas phase change of PFH to achieve the "internal bombing" of the thrombus and promote probe infiltration and phase transition thrombolysis. The in vivo and in vitro experiments were carried out to verify its targeting and multimodal imaging effects. The thrombolytic effect and mechanism of a new high-efficiency thrombolysis method for drug-phase transition thrombolysis were studied. Multi-modal imaging was used to evaluate the thrombolytic process and effect in real time. We aim to develop a efficient, convenient, economical, and non-invasive "all-in-one" thrombus molecular probe that combines diagnosis and treatment to achieve rapid and accurate diagnosis and treatment of thrombosis.